An Efficacy, Safety, Tolerability, Immunogenicity, and Lot-Consistency Clinical Trial of a 6-Valent OspA-Based Lyme Disease Vaccine (VLA15) — VALOR

Lyme Disease Clinical Trial

Official title:
A Phase 3, Multicenter, Placebo-Controlled, Randomized, Observer-Blinded Trial to Evaluate the Efficacy, Safety, Tolerability, Immunogenicity, and Lot Consistency of a 6-Valent OspA-Based Lyme Disease Vaccine in Healthy Participants ≥5 Years of Age

Status Active, not recruiting

Clinical Trial Summary

The main purpose of this clinical study is to evaluate a 6-valent OspA-based Lyme disease vaccine (VLA15) for prevention of Lyme disease within North America and Europe. Approximately 9,400 healthy participants (this number excludes participants from 8 sites which were terminated for quality issues) 5 years and older will be recruited from areas with high levels of endemic Lyme disease to receive VLA15 or placebo (an inactive substance consisting of saltwater). Each participant will have about a 50% chance of receiving VLA15 and about a 50% chance of receiving placebo. A subset of participants will receive VLA15 from 3 different lots or placebo (1:1:1:3 ratio) to assess lot equivalence. Participants will receive a 3-dose primary vaccination series at about 0, 2, and 5 to 9 months and then receive a booster dose about 12 months after end of primary vaccination series. Vaccination of participants will occur at a time of year such that the primary series is completed before the peak Lyme disease season followed by a booster dose just prior to the beginning of the second Lyme disease season. A subset of participants will be followed for a third Lyme disease season. Comparison will be made between the Lyme disease cases of people receiving the study vaccine to those of the people who are not. This will help us determine if the study vaccine is safe and effective. If enrolled, participants will need to visit the research site at least 7 times during the study, and for a subset of participants up to 9 times. There will also be at least 5 telephone contacts. It is expected that each participant will take part in this study for up to about 2 and a half years. The subset of participants followed for a third Lyme disease season will take part in this study for up to about to 3 and a half years.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Lyme Disease

Clinical Trial Details

NCT number	NCT05477524
Study type	Interventional
Source	Pfizer
Contact
Status	Active, not recruiting
Phase	Phase 3
Start date	August 4, 2022
Completion date	December 26, 2025

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01207739` - Persistent Lyme Empiric Antibiotic Study Europe	Phase 4
Terminated	`NCT04577053` - PEMF Therapy to Treat Lingering Symptoms of Lyme Disease After Treatment With Antibiotics	N/A
Completed	`NCT04867473` - Feasibility of Teleyoga for Treatment of Lyme Disease	N/A
Recruiting	`NCT04038346` - Symptomatic Management of Lyme Arthritis	Phase 3
Completed	`NCT01143558` - Searching for Persistence of Infection in Lyme Disease	Early Phase 1
Withdrawn	`NCT04318925` - Evaluation and Follow-up of People With Tick-borne Diseases
Terminated	`NCT03581279` - Detection of Borrelia Bacteria in Early Stage Lyme Borreliosis Using the T2Lyme Panel	N/A
Enrolling by invitation	`NCT05041595` - Lyme Disease Diagnostic Assay - Collection of Whole Blood
Recruiting	`NCT03981874` - Peripheral Facial Paralysis Sequelae in Lyme Disease Among Children	N/A
Recruiting	`NCT03963635` - Novel Diagnostics for Early Lyme Disease
Terminated	`NCT03084614` - CD8 Reactivity to Microorganisms in Blood and Breast Milk
Recruiting	`NCT04835792` - Biomarker Study of Previously Treated Lyme Disease Volunteers in Comparison to Healthy Volunteers
Recruiting	`NCT06397794` - Navigating Pregnancy and Parenthood With Lyme Disease
Recruiting	`NCT04148222` - A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Lyme Disease
Terminated	`NCT03201042` - Lyme Test Indication Combinations (LyTIC) Study
Completed	`NCT01368341` - Comparing 3 Antibiotic Regimes for Erythema Migrans in General Practice	Phase 4
Terminated	`NCT00958139` - Passive Prophylaxis of Lyme Disease Using Permethrin Treated Clothes	Phase 3
Recruiting	`NCT00001539` - A Comprehensive Clinical, Microbiological and Immunological Assessment of Patients With Suspected Post Treatment Lyme Disease Syndrome and Selected Control Populations
Recruiting	`NCT03501407` - Understanding Tick-borne Diseases
Completed	`NCT04422314` - ImmuneSense Lyme Study

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.